Advertisement

Frontiers of Medicine

, Volume 11, Issue 2, pp 297–305 | Cite as

Innovative development path of ethnomedicines: a case study

  • Zhaoyun Zhu
  • Yali Gui
  • Li Wang
  • Ting Wang
  • Yang Yang
  • Yunzhuang Niu
  • Dehuan Fu
  • Jingkun Wang
  • Tao Cui
Commentary
  • 43 Downloads

Abstract

Innovative development extends the vitality of ethnomedicines. Developing ethnomedicines is not only beneficial to the public but also to the related industry and transforms economic growth, driving local social and economic development further. Its economic benefit can be used to optimize and promote the hardware and software of the platform, as well as support the sustainable development of ethnomedicines. Apart from research and discussion on the innovative development of ethnomedicines on the basis of theory and regulations, this series of articles also summarizes cases that are conducive to the overall understanding of the necessity and feasibility of the innovative development. In terms of industrial development, large enterprises and products, such as Yunnan Baiyao, Guizhou Miao ethnomedicines, Cheezheng Tibetan Medicine, products developed from Dengzhanhua (Erigeron breviscapus), the Gold series of Yi ethnomedicines, and products developed from Sanqi (Panax notoginseng), in China are introduced and summarized, focusing on resource superiority, sustainable innovation, standard research and development, and production, as well as intellectual property protection.

Keywords

ethnomedicine industry resource advantages continuous innovation standardized development research intellectual property protection 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Notes

Acknowledgements

We would like to thank Yunnan Provincial Science and Technology Department for continuously supporting studies on ethnomedicines.

References

  1. 1.
    Meng CY, Xiang G, Gong LM. Elements of the mechanism to implement the green sustainable innovation of Yunnan Baiyao. Natl Bus $ Econ Theory Res (Quan Guo Shang Qing $ Jing Ji Li Lun Yan Jiu) 2006; (8):79, 96–97 (in Chinese)Google Scholar
  2. 2.
    The Research Group on “Chinese Enterprises’ Success—A Case Study of Yunnan Baiyao”. The successful path of Yunnan Baiyao. Beijing: Mechanical Industry Press, 2013 (in Chinese)Google Scholar
  3. 3.
    Yunnan Baiyao Group Co. Ltd. 2015 Annual Report of Yunnan Baiyao Group Co., Ltd. Kunming: Yunnan Baiyao Group Co., Ltd. 2016 (in Chinese)Google Scholar
  4. 4.
    Yunnan Baiyao Group Co. Ltd. 2015 Social Responsibility Report of Yunnan Baiyao Group Co., Ltd. Kunming: Yunnan Baiyao Group Co., Ltd. 2016 (in Chinese)Google Scholar
  5. 5.
    Ran MX. Evaluation of Guizhou Miao ethnomedicines research and the modernization of traditional medicine. J Chin Med Materls (Zhong Yao Cai) 2010; 33(2): 163–167 (in Chinese)Google Scholar
  6. 6.
    Ran MX. Recent development of Guizhou Miao medicine. Chin Tradit Herb Drug (Zhong Cao Yao) 2001, 24(5): 324–325 (in Chinese)Google Scholar
  7. 7.
    Tu LN. The industrial output of Guizhou folk medicine ranks first in the country. Guizhou Daily 2014–08–22(002) (in Chinese)Google Scholar
  8. 8.
    Fu Y. The first national folk medicine research center is established in Guizhou. Economic Information Times 2014–10–24(001) (in Chinese)Google Scholar
  9. 9.
    Cheezheng Tibetan Medicine Co., Ltd. 2015 Annual Report of Cheezheng Tibetan Medicine Co., Ltd. Linzhi: Cheezheng Tibetan Medicine Co., Ltd. (in Chinese)Google Scholar
  10. 10.
    No authors listed. Rustic and determined to write a legend but nice and altruistic to commit to public service —Cheezheng Tibetan Medicine chairman Lei Jufang. Gansu Daily 2011–09–02 (in Chinese)Google Scholar
  11. 11.
    Zhang YS. Cheezheng Tibetan Medicine: protection of intellectual property and Xiaotong Plaster. China Invent Patent (Zhongguo Fa Ming Yu Zhuan Li) 2011; (12):33 (in Chinese)Google Scholar
  12. 12.
    Cheezheng Tibetan Medicine Co., Ltd. 2015 Social Responsibility Report of Cheezheng Tibetan Medicine Co., Ltd. Linzhi: Cheezheng Tibetan Medicine Co., Ltd. (in Chinese)Google Scholar
  13. 13.
    Lan M. Supplement of Yunnan Institute of Materia Medica, Southern Yunnan Materia Medica. Kunming: Yunnan Science and Technology Press, 2011 (in Chinese)Google Scholar
  14. 14.
    Editorial Committee of Flora of China Academy of Sciences. Flora of China, Vol. 74 Asteraceae (a). Beijing: Science Press, 1985: 297, 308 (in Chinese)Google Scholar
  15. 15.
    Yang LM, Gu J, Lin MJ, Ge Q, Li LZ. Research progress in Breviscapine. Tianjin Pharm (Tianjin Yao Xue) 2010; 22(1): 56 (in Chinese)Google Scholar
  16. 16.
    Zhang RW, Yang SY, Lin YY. Study on the chemical constituents of Erigeron breviscapus. China J Pharm (Yao Xue Xue Bao) 1981; 16(1): 68–69 (in Chinese)Google Scholar
  17. 17.
    Yang SY. A new drug for cardiovascular and cerebrovascular diseases — Yimaikang tablets. Chin J Hosp Pharm (Zhongguo Yi Yuan Yao Xue Za Zhi) 1990; 10(1): 26 (in Chinese)Google Scholar
  18. 18.
    Yang SY. Observation of the efficacy of erigeron injection in treating 214 cases of hemiplegia. Chin J Neurol Psychiatry (Zhonghua Shen Jing Jing Shen Ke Za Zhi) 1979; 12(1): 44 (in Chinese)Google Scholar
  19. 19.
    Yang SC, Xu SZ, Wen GS, Liu YG, Xiao FH. Study on the phenotypic diversity of Erigeron breviscapus germplasm. Acta Bot Boreali-Occident Sin (Xi Bei Zhi Wu Xue Bao) 2008; 28(8): 1573 (in Chinese)Google Scholar
  20. 20.
    Feng DX, Chen B, Dang CL, Wang CY. Allozyme and karyotype analysis of three populations of Breviscapus in Yunnan. Acta Botanica Yunnanica (Yunnan Zhi Wu Yan Jiu) 2002; 24(6): 754 (in Chinese)Google Scholar
  21. 21.
    Zhang WD, Chen WS, Kong DY, Li HT, Wang YH, Liu WY. Study on the chemical constituents of Erigeron. Chin Pharmacol J (Zhongguo Yao Xue Za Zhi) 2000; 35(8): 514–516 (in Chinese)Google Scholar
  22. 22.
    Zhou SJ. Pharmacody progress and clinical evaluation of Dengzhanxisin preparation. Eval Anal Drug-Use Hosp China (Zhongguo Yi Yuan Yong Yao Ping Jia Yu Fen Xi) 2006; 6(1):22–23 (in Chinese)Google Scholar
  23. 23.
    Li WJ, Tao CG, Peng C. Pharmacokinetics study of the total coffee ester of erigeron injection in rats. Pharmocol Clin Chin Mater Med (Zhong Yao Yao Li Yu Lin Chuang) 2007; 23(2): 26–28 (in Chinese)Google Scholar
  24. 24.
    Dong XD, Deng YJ, Chen C, Cao YC, Cui LL, Wang XY. Preparation of breviscapine cationic liposomes. Chin J New Drugs (Zhongguo Xin Yao Za Zhi) 2010; 19(12): 1075–1079 (in Chinese)Google Scholar
  25. 25.
    Zhang JY, Guo JX, Huang LS. Investigation of the formula of breviscapin dispersed table. Strait Pharm J (Hai Xia Yao Xue) 2004; 16(1): 27–28 (in Chinese)Google Scholar
  26. 26.
    Liu H, Yang XL, Zhou LZ, Wang Y, Tang R, Xu HB. Preparation and in vitro release characteristics of scutellarin sustained-release pills. Pharm Care Res (Yao Xue Fu Wu Yu Yan Jiu) 2004; 4(1): 30–32 (in Chinese)Google Scholar
  27. 27.
    Yang AP, Li ZA. Erigeron breviscapus combined pantoprazole in the treatment of 56 cases of peptic ulcer. Guangdong Med J (Guangdong Yi Xue) 2007; 28(7): 1172 (in Chinese)Google Scholar
  28. 28.
    Zhang W, Yang SC, Zhang GH, Su B. Research on the development situation and countermeasure of Erigeron breviscapus plant production. China J Chin Mater Med (Zhongguo Zhong Yao Za Zhi) 2013; 38(14): 2227–2230 (in Chinese)Google Scholar
  29. 29.
    Yang SC, Wu DC, Wang PL, Wang JW. Assessment of environmental conditions on a GAP basis of Erigeron breviscapus in Honghe region. Res Pract Chin Med (Xian Dai Zhong Yao Yan Jiu Yu Shi Jian) 2006; 20(1): 9 (in Chinese)Google Scholar
  30. 30.
    Wang PL, Yang SC, Yang JW. Description and collection of Erigeron breviscapus germplasm resources in Yunnan. Res Pract Chin Med (Xian Dai Zhong Yao Yan Jiu Yu Shi Jian) 2007; 22(2): 25 (in Chinese)Google Scholar
  31. 31.
    Wang N, Yang ZX, Yang SY. Retrospect and prospect of the research and development of Erigeron breviscapus. Yunnan J Tradit Chin Med Mater Med (Yunnan Zhong Yi Zhong Yao Za Zhi) 2012; 33(5): 69–72 (in Chinese)Google Scholar
  32. 32.
    Zeng YL. Dian Ren Tian Yan —Yunnan Ethnomedicine. Kunming: Yunnan Education Publishing House, 2000 (in Chinese)Google Scholar
  33. 33.
    Sun Y, Liu B. In vitro percutaneous penetration; an experimental study of the Gold series of Zhongtong products. Chin Arch Tradit Chin Med (Zhonghua Zhong Yi Yao Xue Kan) 2014; 32(5): 1109–1111 (in Chinese)Google Scholar
  34. 34.
    Cui T, Peng LF, Luo XL, Feng LP, Li JT. Investigation of TLC identification in the product quality standards of the Gold product series. Yunnan J Tradit Chin Med Mater Med (Yunnan Zhong Yi Zhong Yao Za Zhi) 2005; 26(6): 52–53 (in Chinese)Google Scholar
  35. 35.
    Li GL. Modern research and development of Panax notoginseng (Sanqi) (I). World J Integ Tradit Western Med (Shi Jie Zhong Xi Yi Jie He Za Zhi) 2008; 3(10): 619–623 (in Chinese)Google Scholar
  36. 36.
    Gao CZ. Revised description of Sanqi original plants. Bull Chin Mater Medica (Zhong Yao Tong Bao) 1985; 10(11): 13–15 (in Chinese)Google Scholar
  37. 37.
    Wang ZP, Hua Y. Review of the research on the chemical constituents and pharmacological effects of Panax notoginseng leaf. Chin J Ethomed Ethnopharm (Zhongguo Min Zu Min Jian Yi Yao) 2008; 17(1): 76–78 (in Chinese)Google Scholar
  38. 38.
    Li GL. Modern research and development of Panax notoginseng (Sanqi) (II). World J Integ Tradit Western Med (Shi Jie Zhong Xi Yi Jie He Za Zhi) 2008; 3(11): 687–691 (in Chinese)Google Scholar
  39. 39.
    Wu WF, Zhang ZH, Chen YX. Research progress in the technology of new Panax notoginseng formulation. Hebei Med J (Hebei Yi Yao) 2011; 33(22): 3464–3465 (in Chinese)Google Scholar
  40. 40.
    Xu JB, Chen QQ, Wen Z, Zhao Y, Zhao XM, Long Y, Gao T. Progress in the clinical application of a single herb of Panax notoginseng. Chin J Clin Ration Drug Use (Lin Chuang He Li Yong Yao) 2013; 6(4C): 157–159 (in Chinese)Google Scholar
  41. 41.
    Chen ZJ, Yang L, Wang Y, Yang JZ, Wei ML, Huang TW, Wang BY. Advances in the cultivation of Panax notoginseng. J Wenshan Univ (Wenshan Xue Yuan Xue Bao) 2012; 25(6): 1–12 (in Chinese)Google Scholar

Copyright information

© Higher Education Press and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Zhaoyun Zhu
    • 1
  • Yali Gui
    • 1
  • Li Wang
    • 1
  • Ting Wang
    • 1
  • Yang Yang
    • 1
  • Yunzhuang Niu
    • 1
  • Dehuan Fu
    • 1
  • Jingkun Wang
    • 1
  • Tao Cui
    • 1
  1. 1.Yunnan Institute of Materia MedicaInnovation and R & D Center of Yunnan Baiyao Group Co., Ltd., and Yunnan Province Company Key Laboratory for New Drug Research and Development of TCM and EthnomedicinesKunmingChina

Personalised recommendations